XENO (Xeno Transplants) Debt-to-Equity: 14.58 (As of Mar. 2008)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Xeno Transplants Debt-to-Equity?

Xeno Transplants XENO Debt-to-Equity is 14.58 as of Mar. 2008.

Xeno Transplants's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2008 was $0.48 Mil. Xeno Transplants's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2008 was $0.00 Mil. Xeno Transplants's Total Stockholders Equity for the quarter that ended in Mar. 2008 was $0.03 Mil. Xeno Transplants's debt to equity for the quarter that ended in Mar. 2008 was 14.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Xeno Transplants's Debt-to-Equity or its related term are showing as below:

XENO's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Xeno Transplants  (OTCPK:XENO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Xeno Transplants Debt-to-Equity Related Terms

Xeno Transplants Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Xeno Transplants's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeno Transplants Debt-to-Equity Chart

Xeno Transplants Annual Data
Trend Jun05 Jun06 Jun07
Debt-to-Equity
0.00 0.00 0.00

Xeno Transplants Quarterly Data
Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2.16 14.58

XENO vs PRTX, GWSN, HSTC: Debt-to-Equity Comparison

For the Biotechnology subindustry, Xeno Transplants's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeno Transplants Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeno Transplants's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Xeno Transplants's Debt-to-Equity falls into.


Xeno Transplants Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Xeno Transplants's Debt to Equity Ratio for the fiscal year that ended in Jun. 2007 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.386
=0.00

Xeno Transplants's Debt to Equity Ratio for the quarter that ended in Mar. 2008 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.481 + 0) / 0.033
=14.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 14.58 mean?
Xeno Transplants (XENO) has a Debt-to-Equity of 14.58 as of Mar. 2008. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xeno Transplants and its competitors.
Is Xeno Transplants' Debt-to-Equity too high?
Xeno Transplants' current Debt-to-Equity is 14.58. The Biotechnology industry median Debt-to-Equity is 0.16. Xeno Transplants' value of 14.58 is 9012.5% above this industry median.
How does Xeno Transplants' Debt-to-Equity compare to PRTX and GWSN?
Xeno Transplants' Debt-to-Equity of 14.58 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. Xeno Transplants' value of 14.58 is 9012.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeno Transplants's current Debt-to-Equity of 14.58 is 9012.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xeno Transplants and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeno Transplants's current Debt-to-Equity is 14.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeno Transplants stock overvalued right now?
Xeno Transplants (XENO) has a current Debt-to-Equity of 14.58. The current Debt-to-Equity is 14.58 and 9012.5% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Xeno Transplants (XENO), the current Debt-to-Equity is 14.58 as of Mar. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xeno Transplants Business Description

Address 143 Gardner Road, Brookline, MA, USA, 02445
Xeno Transplants Corp is a bio-technology research and development company, which intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.